Location Seattle, Washington, United States Regions Greater Seattle Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn X (Twitter) View on X
Alan Snow is the Founder and Chairman of the Company's Board of Directors. He previously served as a Research Associate Professor of Pathology at the University of Washington, and is a world-recognized authority on the role of proteoglycans in Alzheimer's and amyloid diseases. He holds a B.S. in Biology/Chemistry from Bowling Green
State University in Ohio, an M.S. in Anatomy from University of Western Ontario (London, Ontario, Canada, and a Ph.D. in Pathology from Queen's University (Kingston, Ontario, Canada). At Queen's University, Dr. Snow worked in the laboratory of Dr. Robert Kisilevsky, one of the founders of Neurochem Inc. Dr. Snow's thesis work led to new discoveries concerning the pathogenic role that proteoglycans and glycosaminoglycans play in amyloid diseases.
At the University of Washington, Dr. Snow was the first to identify and demonstrate specific proteoglycans in amyloid deposits in Alzheimer's disease. Dr. Snow also co-authored a number of papers with Nobel laureate Dr. Stanley Prusiner and was the first to identify specific proteoglycans in the brain amyloid deposits in a variety of prion diseases. Dr. Snow is the author of more than 50 scientific publications and has presented his research on amyloid disease and proteoglycans at over 120 scientific meetings.
Dr. Snow founded ProteoTech in 1996, then left the University of Washington in 1999 to serve as the Company's Chairman, President, acting CEO and CSO. He was instrumental in personally writing and acquiring over $10 million in grant funding from the NIH SBIR and The Michael J. Fox Foundation for Parkinson's research LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) program. He helped hire corporate and patent lawyers, as well as regulatory and scientific advisors, and recruited world-class research scientists and key management and consultant positions for the Company. He helped negotiate and write/edit business contracts and agreements for various contract research organizations and university collaborations, and guided major drug development programs for ProteoTech in Alzheimer's, Parkinson's, type 2 diabetes and systemic amyloidosis. He helped write and guided patent lawyers and patent agents on more than 165 patents pertaining to new therapeutics and diagnostics platform for amyloid diseases and proteoglycan technologies.
